![]() |
市場調查報告書
商品編碼
1865407
全球培養肉成分市場預測(至2032年):按肉類型、細胞來源、培養基、支架和組織化技術、技術、應用和地區進行分析Cultivated Meat Composition Market Forecasts to 2032 - Global Analysis By Meat Type, Cell Source, Growth Medium, Scaffolding & Texturization Technique, Technology, Application and By Geography |
||||||
據 Stratistics MRC 稱,2025 年全球培養肉成分市場預計價值 4,306 萬美元,預計在預測期內將以 21.3% 的複合年成長率成長,到 2032 年達到 1.6639 億美元。
培養肉的組成是指透過組織工程技術生產的培養肉的細胞和生化成分。它通常包含肌肉纖維、脂肪細胞和結締組織,這些組織來自在營養豐富的培養基中培養的動物幹細胞。最終產品的目標是複製傳統肉類的質地、風味和營養成分。其組成會因細胞類型、支架材料和培養條件的不同而有所差異,並且可以進行客製化,以提高蛋白質含量、脂肪比例和微量營養素水平,從而滿足特定應用的需求。
對非殘忍、非屠宰蛋白質來源的需求日益成長
人們對動物福利的日益關注,以及對畜牧業相關環境問題的擔憂,正在加速人們對培養肉解決方案的興趣。培養肉提供了一種可行的蛋白質消費選擇,避免了屠宰帶來的倫理困境,符合彈性素食者、素食者和具有氣候意識的消費者的價值觀。組織工程和生物反應器領域的技術突破進一步推動了人造肉的規模化生產。監管政策的調整和對細胞農業Start-Ups的大量投資也促進了這一轉變。
細胞株規模化和保持均一性的技術挑戰
在大規模批量生產中維持細胞活力和均勻性仍然是一項複雜的挑戰,通常需要精確控制培養基、溫度和氧氣供應。細胞行為和分化的差異會導致質地、口感和營養成分的異質性。此外,生物反應器系統和無菌環境的成本和複雜性也增加了操作難度。這些技術瓶頸正在減緩技術的應用,並限制生產商滿足日益成長的需求的能力。
生產富含Omega-3脂肪酸的肉類的可能性
與傳統肉品不同,培養肉可以添加有益成分,例如有助於心血管和認知健康的Omega-3 Omega-3脂肪酸。這為機能性食品的開發鋪平了道路,使生產商能夠提供針對注重健康的消費者的高級產品。代謝工程和精準發酵技術的進步使得在細胞培養過程中添加生物活性成分成為可能。這些營養強化措施有望使培養肉不僅成為符合倫理的選擇,而且成為一種營養更優的食品。
對特殊成分的依賴
這些原料大多來自小眾供應商,因此生產過程極易受到供應中斷和價格波動的影響。此外,某些原材料的專有性質可能導致智慧財產權限制,從而阻礙跨行業合作。隨著需求的成長,確保這些原料的穩定且經濟高效的供應至關重要。如果原料來源不夠多元化,培養肉生產者可能難以維持盈利和業務永續營運。
新冠疫情加速了人們對包括培養肉在內的替代蛋白來源的興趣,這源於人們對通用感染疾病和食品安全的日益關注。雖然早期的封鎖措施擾亂了研發進度和供應鏈,但這場危機也凸顯了傳統肉類生產系統的脆弱性。為此,投資者和政府開始優先考慮食品創新和生物安全,從而增加了對細胞農業的資金投入和監管支持。疫情也促使消費者轉向更健康、永續的飲食,為培養肉的普及創造了有利環境。
預計在預測期內,動物源性細胞細分市場將佔據最大的市場佔有率。
預計在預測期內,以動物源性細胞為主的培育肉製品將佔據最大的市場佔有率,這主要得益於其能夠複製真實肉類的特性,包括風味、質地和營養價值。這些細胞提取自家禽、牛、豬等牲畜,是培養肉的基礎。親和性也進一步推動了其廣泛應用。隨著各公司不斷改進細胞分離和培養技術,預計這一領域仍將是商業化生產的核心。
預計在預測期內,植物來源培養基配方細分市場將呈現最高的複合年成長率。
預計在預測期內,植物來源培養基配方領域將達到最高成長率,主要得益於減少對牛等動物源性培養基依賴的需求。這些製劑提供了經濟高效且符合倫理的替代方案,有助於擴大生產規模並提高消費者接受度。植物蛋白水解物、藻類萃取物和重組生長因子等領域的創新,使得細胞能夠在不影響品質的前提下高效生長。此外,監管機構要求消除動物性成分的壓力以及消費者對純素培養肉解決方案日益成長的需求,也推動了該領域的成長。
預計亞太地區將在預測期內佔據最大的市場佔有率,這主要得益於快速的都市化、不斷成長的可支配收入以及人們對糧食安全日益成長的擔憂。中國、新加坡和日本等國家正積極投資細胞農業,以應對傳統肉類生產帶來的環境和公共衛生挑戰。政府主導的措施、支持性的法規結構以及與全球生物技術公司的策略合作正在加速市場滲透。
在預測期內,北美預計將實現最高的複合年成長率,這得益於其強大的研發基礎、創業投資投資以及不斷完善的監管體系。美國食品藥物管理局(FDA)和美國農業部(USDA)已開始核准培養肉肉品,為其進入市場鋪平了道路。領先的Start-Ups和學術機構正在推動細胞培養技術、生物反應器設計和培養基最佳化方面的創新。此外,消費者對永續性和動物福利意識的不斷提高也推動了對非屠宰蛋白來源的需求。
According to Stratistics MRC, the Global Cultivated Meat Composition Market is accounted for $43.06 million in 2025 and is expected to reach $166.39 million by 2032 growing at a CAGR of 21.3% during the forecast period. Cultivated meat compositions are the cellular and biochemical makeup of lab-grown meat produced through tissue engineering. It typically includes muscle fibers, fat cells, and connective tissues derived from animal stem cells cultured in nutrient-rich media. The final product aims to replicate the texture, flavor, and nutritional profile of conventional meat. Composition may vary based on cell type, scaffold material, and growth conditions, with potential for customization to enhance protein content, fat ratios, or micronutrient levels for targeted applications.
Rising demand for cruelty-free and slaughter-free protein sources
Growing awareness of animal welfare, coupled with environmental concerns related to livestock farming, is driving interest in lab-grown meat solutions. Cultivated meat offers a viable path to protein consumption without the ethical dilemmas of slaughter, aligning with the values of flexitarians, vegetarians, and climate-conscious consumers. Technological breakthroughs in tissue engineering and bioreactors are further enabling scalable production of meat analogs. This shift is also supported by regulatory advancements and investment inflows into cellular agriculture startups.
Technical challenges in scaling cell lines and maintaining consistency
Maintaining cell viability and uniformity across large batches remains a complex task, often requiring precise control over growth media, temperature, and oxygenation. Variability in cell behavior and differentiation can lead to inconsistencies in texture, taste, and nutritional profile. Moreover, the cost and complexity of bioreactor systems and sterile environments add to operational challenges. These technical bottlenecks are slowing down mass adoption and limiting the ability of producers to meet growing demand.
Potential to create meat with enhanced omega-3s
Unlike conventional meat, lab-grown compositions can be engineered to include beneficial compounds such as omega-3 fatty acids, which support cardiovascular and cognitive health. This opens avenues for functional food innovation, allowing producers to target health-conscious consumers with premium offerings. Advances in metabolic engineering and precision fermentation are enabling the incorporation of bioactive ingredients during cell cultivation. Such enhancements could position cultivated meat as not just an ethical choice, but a nutritionally superior one.
Dependence on specialized inputs
Many of these components are sourced from niche suppliers, making the production process vulnerable to disruptions and price volatility. Additionally, the proprietary nature of some inputs can lead to intellectual property constraints, limiting cross-industry collaboration. As demand scales, securing consistent and cost-effective access to these materials will be critical. Without robust input diversification, cultivated meat producers may struggle to maintain profitability and operational resilience
The COVID-19 pandemic accelerated interest in alternative protein sources, including cultivated meat, as concerns over zoonotic diseases and food safety intensified. While initial lockdowns disrupted R&D timelines and supply chains, the crisis also highlighted the fragility of traditional meat production systems. In response, investors and governments began prioritizing food innovation and biosecurity, leading to increased funding and regulatory support for cellular agriculture. The pandemic also shifted consumer behavior toward health-conscious and sustainable eating, creating a favorable environment for cultivated meat adoption.
The primary animal-derived cells segment is expected to be the largest during the forecast period
The primary animal-derived cells segment is expected to account for the largest market share during the forecast period propelled by, ability to replicate authentic meat characteristics, including flavor, texture, and nutritional content. These cells, sourced from livestock such as poultry, beef, and pork, serve as the foundational building blocks for cultivated meat products. Their compatibility with existing bioprocessing technologies and regulatory familiarity further contribute to their widespread adoption. As companies refine cell isolation and propagation techniques, this segment is expected to remain central to commercial-scale production.
The plant-based media formulations segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the plant-based media formulations segment is predicted to witness the highest growth rate, driven by the need to reduce reliance on animal-derived growth media such as fetal bovine serum. These formulations offer a cost-effective and ethically aligned alternative, supporting scalability and consumer acceptance. Innovations in plant protein hydrolysates, algal extracts, and recombinant growth factors are enabling efficient cell proliferation without compromising quality. The segment's growth is also supported by regulatory pressure to eliminate animal inputs and the rising demand for fully vegan cultivated meat solutions.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, fueled by rapid urbanization, rising disposable incomes, and growing concerns over food security. Countries such as China, Singapore, and Japan are actively investing in cellular agriculture to address environmental and public health challenges associated with traditional meat production. Government-backed initiatives, supportive regulatory frameworks, and strategic partnerships with global biotech firms are accelerating market penetration.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by, strong R&D infrastructure, venture capital activity, and progressive regulatory developments. The U.S. Food and Drug Administration and USDA have begun approving cultivated meat products, paving the way for market entry. Leading startups and academic institutions are driving innovation in cell culture techniques, bioreactor design, and media optimization. Additionally, consumer awareness around sustainability and animal welfare is fostering demand for slaughter-free protein options.
Key players in the market
Some of the key players in Cultivated Meat Composition Market include Mosa Meat, Aleph Farms, Upside Foods, Eat Just (GOOD Meat), Meatable, SuperMeat, Shiok Meats, BlueNalu, Finless Foods, Avant Meats, Higher Steaks, Wildtype, TurtleTree, Integriculture and MeaTech.
In September 2025, Aleph Farms signed an MoU with The Cultured Hub to establish a European cultivation/production presence in Kemptthal, Switzerland. The agreement is positioned as a capital-efficient, locally embedded production model to bring "Aleph Cuts" to European markets.
In April 2025, Meatable announced a collaboration with TruMeat (and other partners) to accelerate cost-effective cultivated-meat production and build a commercial facility in Singapore to lower production costs and scale volumes. The partnership is intended to develop manufacturing and formulation capabilities for market-ready products at competitive cost points.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.